BRIEF published on 05/19/2026 at 07:05, 1 month 7 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 1 month 7 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
BRIEF published on 05/19/2026 at 07:05, 1 month 7 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 1 month 7 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 1 month 7 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
PRESS RELEASE published on 05/19/2026 at 07:00, 1 month 7 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 2 months 8 days ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 2 months 8 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 2 months 8 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 2 months 8 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
Published on 06/26/2026 at 14:05, 3 hours 48 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 53 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 53 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 17:40, 13 minutes ago Rainbow World Group announces that its subsidiary Rainbow Images is about to commence legal proceedings to enforce image-rights and intellectual-property agreements related to footballer Yan Diomande
Published on 06/26/2026 at 17:40, 13 minutes ago Rainbow World Group annonce que sa filiale Rainbow Images s’apprête à engager une procédure judiciaire afin de faire respecter des accords relatifs aux droits d’image et à la propriété intellectuelle
Published on 06/26/2026 at 17:05, 48 minutes ago NAKIKI SE Receives an Adverse Opinion on Its 2024 Financial Statements and Management Report
Published on 06/26/2026 at 17:00, 53 minutes ago Darwin AG Announces Results of the 2026 Annual General Meeting
Published on 06/26/2026 at 16:38, 1 hour 15 minutes ago Cairn Homes Plc: Notice of H1 2026 Trading Update
